Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
While there are benefits to genetic screening during pregnancy, parents must not let their desire for a genetically perfect child allow them to terminate a pregnancy because of non-medical factors.
The president of the Association of American Medical Colleges gives reasons why medical schools need to continue affirmative action admissions policies.
Physicians need to take an active role in improving the genetic literacy of the general population and also push for public health policies that make new genetic tools available to everyone.
Dr Katherin M. Duthie joins Ethics Talk to discuss her article, coauthored with Dr Kathryn A. Dong: “How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD?”